Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 45 of 95, showing 5 Applications out of 471 total, starting on record 221, ending on 225

# Protocol No Study Title Investigator(s) & Site(s)

221.

ECCT/19/11/04   Second line switch to Dolutegravir (2SD) study
    Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults from Ritonavir boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial               
Principal Investigator(s)
1. Loice Achieng
Site(s) in Kenya
1. Kenyatta National Hospital (Nairobi City county)
2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
3. Thika Level 5 Hospital (Kiambu county)
4. Kiambu Level 5 Hospital (Kiambu county)
 
View

222.

ECCT/19/11/05   Point-of-care Urine Monitoring of Adherence (PUMA)
    Point-of-care Urine Monitoring of Adherence (PUMA): Testing a Real-Time Urine Assay of Tenofovir in PrEP   Pilot trial to examine the feasibility, acceptability and impact on longer-term adherence of an intervention using a new urine-based tenofovir adherence assay       
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR PHRD (THIKA) PROJECT
 
View

223.

ECCT/19/11/06   Optimize LNG EC
    An Open Label Phase 2 Pharmarcokinetic Study to Evaluate Double - Dose Levonorgestrel Emergency Contraception in Combination withEfavirenz Based Antiretroviral Therapy or Rifampicin Containing Anti - Tuberculosis Therapy. A5375   
Principal Investigator(s)
1. Lucy Chepkurui Koech
Site(s) in Kenya
KEMRI/WRP Kericho
 
View

224.

ECCT/19/12/01   BOHEMIA PK400
    Mosquitocidal effect and pharmacokinetics of different ivermectin dose regimens in preparation for BOHEMIA cluster randomized controlled trial.   
Principal Investigator(s)
1. Marta Ferreira Maia
Site(s) in Kenya
Kilifi
 
View

225.

ECCT/19/12/02   VPM1002 Phase III PoI
    A multicenter, Phase III double blind, randomized active controlled study to evaluate efficacy and safety of VPM1002 in comparison with BCG in prevention of Mycobacterium tuberculosis infection in newborn infants.     
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. KEMRI-CRDR Nairobi (Nairobi City county)
2. KEMRI-CRDR Siaya (Siaya county)
 
View